News - 04 Jan `23Update on Vitiligo Drug Development in 2023

New

Pune-based startup Ahammune Biosciences has recently completed the phase 1 clinical trials of its investigational new drug AB1001, being developed as a topical therapy for vitiligo. 

Dr T. Balganesh, Chairman of Ahammune’s Board said, “Vitiligo is a much neglected disease and specific treatments for the disease are not available. AB1001 is a novel class of compounds, discovered and developed at Ahammune, that has the potential to not only limit the progression of the disease but also reverses the pigmentation loss. The successful completion of Phase 1 of the molecule brings a much wanted treatment closer to the patients. We are looking forward to the compound becoming a drug shortly.”
 
Ahammune Biosciences and Ahmedabad-based Veeda Clinical Research had partnered for the first in human studies with Ahammune’s investigational new drug AB1001.

Source



      FAQOther Questions

      • What causes vitiligo?

        Surprisingly, the causes of vitiligo are yet to be precisely established. Researchers know the cause is pre-wired in your genes, just waiting for a bad luck moment. In about hal...

      • Is there a link between vitiligo and depression?

        Depression and anxiety are often linked with vitiligo, significantly impacting a person’s quality of life. The connection stems from the shared origin of the skin and brain duri...

      • Is it Bitiligo? Vitaligo? Veteligo?

        There are so many different ways that people try and spell or even pronounce Vitiligo.  Here are some common mis-spellings: bitiligo, vitigo, vitaligo, vitilago, vitiglio, vita...